Intervention
Triptorelin
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 19 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
19 shownAssessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CTNCT07455903 · 2026-07-29
RECRUITINGStereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialNCT06378866 · 2024-06-03
RECRUITINGElacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast CancerNCT05982093 · 2023-02-03
RECRUITINGTreating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET ImagingNCT04423211 · 2020-10-08
RECRUITINGStandard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerNCT03678025 · 2018-09-24
RECRUITINGEvaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer PatientsNCT06473259 · 2016-12-16
RECRUITINGA Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast CancerNCT05896566 · 2024-01-23
COMPLETEDTwo Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06
ACTIVE_NOT_RECRUITINGTesting the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE StudyNCT04484818 · 2021-03-01
ACTIVE_NOT_RECRUITINGTwo Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21
ACTIVE_NOT_RECRUITINGAndrogen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer PatientsNCT04248621 · 2020-01-23
UNKNOWNNeoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer PatientsNCT04659551 · 2017-10-05
COMPLETEDManagement of Castration-Resistant Prostate Cancer with OligometastasesNCT02685397 · 2016-10-01
ACTIVE_NOT_RECRUITINGMicro RNAs to Predict Response to Androgen Deprivation TherapyNCT02366494 · 2015-04-29
COMPLETEDNeoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in RussiaNCT05800197 · 2014-04-15
UNKNOWNMRI Substudy; Metabolic Changes Due to Iatrogenic HypogonadismNCT02102646 · 2014-04-01
COMPLETEDAnti-Mullerian Hormone (AMH) as Marker of Ovarian ReserveNCT02113553 · 2013-05-01
TERMINATEDInvestigation of Early Hormonotherapy Efficacy of Prostate CancerNCT00375687 · 2005-08-01
UNKNOWNSuppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast CancerNCT00066690 · 2003-12-17
COMPLETEDCommon conditions
Breast Cancer5Prostate Cancer5Prostate Adenocarcinoma3Biochemically Recurrent Prostate Carcinoma2Stage IVA Prostate Cancer AJCC v82Stage IVB Prostate Cancer AJCC v82Castration Levels of Testosterone1Castration-resistant Prostate Cancer1Castration-resistant Prostate Cancer Patients with Oligometastases1Estrogen Receptor Positive Breast Cancer1Fatty Liver1HER2-negative Breast Cancer1Hormone Receptor Positive Tumor1Hormone Sensitive Prostate Cancer1Hypogonadism1Localized Prostate Carcinoma1Metabolic Syndrome1Metastatic Prostate Carcinoma1Metastatic Prostatic Adenocarcinoma1Metastatic Tumor1Neoadjuvant Endocrine Therapy1Premenopausal Breast Cancer1Progesterone Receptor Positive Tumor1Prostate Carcinoma1Prostatic Neoplasms1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
Leading sponsors
ECOG-ACRIN Cancer Research Group
2
ETOP IBCSG Partners Foundation
2
NRG Oncology
2
Armando Santoro, MD
1
Baptist Health South Florida
1
Blokhin's Russian Cancer Research Center
1
Herlev Hospital
1
Istituto Oncologico Veneto IRCCS
1
Kaunas University of Medicine
1
Mayo Clinic
1
Medical College of Wisconsin
1
Santa Chiara Hospital
1
Sir Mortimer B. Davis - Jewish General Hospital
1
SOLTI Breast Cancer Research Group
1
SWOG Cancer Research Network
1
Trial status mix
RECRUITING6
COMPLETED5
ACTIVE_NOT_RECRUITING4
UNKNOWN3
TERMINATED1
Phase mix
PHASE27
PHASE37
PHASE42
NA1
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.